# Summary statistics - quantitative results

## EQA round: ALB2/26 - Albumin in Urine

Deadline: 2.10.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
$N_{tot}$ = total number of the results
$N_{out}$ = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
$U_{AV}$ = expanded uncertainty of the assigned value (k = 2)
$D_{max}$ = acceptable difference
LL = lower limit
UL = upper limit
$N_{eva}$ = number of the results assessed
$N_{suc}$ = number of successful results
$S_{rel}$ = relative success

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (470) **ACR** | [g/mol] | | | | 257 | | | | | | | | 257 | 208 | 81 |
| **Sample A** | | | | | | | | | | | | | 257 | 213 | 83 |
| (0) not specified | | 2,47 | 0,33 | 13 | 257 | 0 | CVP | 2,47 | 0,05 | 24% | 1,87 | 3,07 | 257 | | |
| **Sample B** | | | | | | | | | | | | | 257 | 249 | 97 |
| (0) not specified | | 4,32 | 0,37 | 8,5 | 257 | 0 | CVP | 4,32 | 0,056 | 24% | 3,28 | 5,36 | 257 | | |
| (369) **Albumin** | [mg/L] | | | | 268 | | | | | | | | 268 | 240 | 90 |
| **Sample A** | | 13,7 | 1,5 | 11 | 268 | | CVP | 13,7 | 0,23 | 30% | 9,59 | 17,9 | 268 | 243 | 91 |
| (1) Abbott | | 14,7 | 0,85 | 5,8 | 63 | 0 | | | | | | | 63 | | |
| (58) Beckman Coulter (AU) | | 13,3 | 0,74 | 5,5 | 40 | 0 | | | | | | | 40 | | |
| (60) Roche | | 14 | 0,77 | 5,5 | 103 | 0 | | | | | | | 103 | | |
| (162) Siemens (Atellica) | | 9,75 | 1,2 | 12 | 38 | 0 | | | | | | | 38 | | |
| (177) Mindray | | 16,3 | 1,1 | 6,8 | 7 | 0 | | | | | | | 7 | | |
| Other | | | | | 17 | 0 | 2x 0, 1x 5, 3x 12, 1x 29, 1x 36, 2x 73, 3x 149, 1x 152, 1x 178, 2x 179 | | | | | | 17 | | |
| **Sample B** | | 55 | 3,5 | 6,3 | 268 | | CVP | 55 | 0,52 | 21% | 43,4 | 66,6 | 268 | 262 | 98 |
| (1) Abbott | | 56,8 | 2,1 | 3,7 | 63 | 0 | | | | | | | 63 | | |
| (58) Beckman Coulter (AU) | | 55,9 | 2,2 | 3,9 | 40 | 0 | | | | | | | 40 | | |
| (60) Roche | | 53,9 | 1,7 | 3,2 | 103 | 0 | | | | | | | 103 | | |
| (162) Siemens (Atellica) | | 50,9 | 2,6 | 5,1 | 38 | 0 | | | | | | | 38 | | |
| (177) Mindray | | 63,2 | 4,2 | 6,7 | 7 | 0 | | | | | | | 7 | | |
| Other | | | | | 17 | 0 | 2x 0, 1x 5, 3x 12, 1x 29, 1x 36, 2x 73, 3x 149, 1x 152, 1x 178, 2x 179 | | | | | | 17 | | |
| (408) **Creatinine** | [mmol/L] | | | | 262 | | | | | | | | 262 | 258 | 98 |
| **Sample A** | | 5,56 | 0,24 | 4,4 | 262 | | CVP | 5,56 | 0,037 | 16% | 4,67 | 6,45 | 262 | 259 | 99 |
| (1) Abbott | | 5,4 | 0,14 | 2,6 | 60 | 0 | | | | | | | 60 | | |
| (46) Erba Lachema | | 5,45 | 0,33 | 6 | 6 | 0 | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 5,49 | 0,46 | 8,4 | 41 | 0 | | | | | | | 41 | | |
| (60) Roche | | 5,64 | 0,23 | 4,1 | 102 | 0 | | | | | | | 102 | | |
| (162) Siemens (Atellica) | | 5,65 | 0,14 | 2,4 | 39 | 0 | | | | | | | 39 | | |
| (177) Mindray | | 5,27 | 0,1 | 2 | 6 | 0 | | | | | | | 6 | | |
| Other | | | | | 8 | 0 | 1x 5, 1x 12, 2x 73, 2x 149, 1x 178, 1x 179 | | | | | | 8 | | |
| **Sample B** | | 12,7 | 0,49 | 3,9 | 262 | | CVP | 12,7 | 0,074 | 16% | 10,6 | 14,8 | 262 | 260 | 99 |
| (1) Abbott | | 12,4 | 0,36 | 2,9 | 60 | 0 | | | | | | | 60 | | |
| (46) Erba Lachema | | 12,5 | 0,61 | 4,9 | 6 | 0 | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 12,9 | 0,59 | 4,6 | 41 | 0 | | | | | | | 41 | | |
| (60) Roche | | 12,9 | 0,48 | 3,7 | 102 | 0 | | | | | | | 102 | | |
| (162) Siemens (Atellica) | | 12,8 | 0,29 | 2,3 | 39 | 0 | | | | | | | 39 | | |
| (177) Mindray | | 12 | 0,12 | 1 | 6 | 0 | | | | | | | 6 | | |
| Other | | | | | 8 | 0 | 1x 5, 1x 12, 2x 73, 2x 149, 1x 178, 1x 179 | | | | | | 8 | | |